Literature DB >> 25943033

CD47 protein expression in acute myeloid leukemia: A tissue microarray-based analysis.

Serena Galli1, Inti Zlobec2, Christian Schürch3, Aurel Perren2, Adrian F Ochsenbein4, Yara Banz5.   

Abstract

Binding of CD47 to signal regulatory protein alpha (SIRPα), an inhibitory receptor, negatively regulates phagocytosis. In acute myeloid leukemia (AML), CD47 is overexpressed on peripheral blasts and leukemia stem cells and inversely correlates with survival. Aim of the study was to investigate the correlation between CD47 protein expression by immunohistochemistry (IHC) in a bone marrow (BM) tissue microarray (TMA) and clinical outcome in AML patients. CD47 staining on BM leukemia blasts was scored semi-quantitatively and correlated with clinical parameters and known prognostic factors in AML. Low (scores 0-2) and high (score 3) CD47 protein expression were observed in 75% and 25% of AML patients. CD47 expression significantly correlated with percentage BM blast infiltration and peripheral blood blasts. Moreover, high CD47 expression was associated with nucleophosmin (NPM1) gene mutations. In contrast, CD47 expression did not significantly correlate with overall or progression free survival or response to therapy. In summary, a BM TMA permits rapid and reproducible semi-quantitative analysis of CD47 protein expression by IHC. While CD47 expression on circulating AML blasts has been shown to be a negative prognostic marker for a very defined population of AML patients with NK AML, CD47 expression on AML BM blasts is not.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acute myeloid leukemia; Bone marrow; CD47; Tissue microarray

Mesh:

Substances:

Year:  2015        PMID: 25943033     DOI: 10.1016/j.leukres.2015.04.007

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  16 in total

1.  PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy.

Authors:  Zhenlin Yang; Jiachen Xu; Renda Li; Yibo Gao; Jie He
Journal:  J Cancer Res Clin Oncol       Date:  2019-09-14       Impact factor: 4.553

2.  CD47 (Cluster of Differentiation 47).

Authors:  Sukhbir Kaur; Jeffrey S Isenberg; David D Roberts
Journal:  Atlas Genet Cytogenet Oncol Haematol       Date:  2021

3.  The CD47 "don't eat me signal" is highly expressed in human ovarian cancer.

Authors:  R M Brightwell; K S Grzankowski; S Lele; K Eng; M Arshad; H Chen; K Odunsi
Journal:  Gynecol Oncol       Date:  2016-08-25       Impact factor: 5.482

Review 4.  Finding new lanes: Chimeric antigen receptor (CAR) T-cells for myeloid leukemia.

Authors:  Suraj Pratap; Zhizhuang J Zhao
Journal:  Cancer Rep (Hoboken)       Date:  2020-01-08

5.  PD-L1 and CD47 co-expression predicts survival and enlightens future dual-targeting immunotherapy in non-small cell lung cancer.

Authors:  Zhenlin Yang; Yue Peng; Wei Guo; Jiachen Xu; Lin Li; He Tian; Renda Li; Lei Liu; Fengwei Tan; Shugeng Gao; Jie He
Journal:  Thorac Cancer       Date:  2021-05-12       Impact factor: 3.500

6.  SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells.

Authors:  Laia Pascual Ponce; Nadja C Fenn; Nadine Moritz; Christina Krupka; Jan-Hendrik Kozik; Kirsten Lauber; Marion Subklewe; Karl-Peter Hopfner
Journal:  Oncotarget       Date:  2017-02-14

7.  Signal regulatory protein alpha blockade potentiates tumoricidal effects of macrophages on gastroenterological neoplastic cells in syngeneic immunocompetent mice.

Authors:  Tomoyuki Abe; Yuka Tanaka; Jinlian Piao; Naoki Tanimine; Naohide Oue; Takao Hinoi; Noel Verjan Garcia; Masayuki Miyasaka; Takashi Matozaki; Wataru Yasui; Hideki Ohdan
Journal:  Ann Gastroenterol Surg       Date:  2018-09-10

8.  Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody.

Authors:  Rama Krishna Narla; Hardik Modi; Daniel Bauer; Mahan Abbasian; Jim Leisten; Joseph R Piccotti; Stephan Kopytek; Brendan P Eckelman; Quinn Deveraux; John Timmer; Dan Zhu; Lilly Wong; Laure Escoubet; Heather K Raymon; Kandasamy Hariharan
Journal:  Cancer Immunol Immunother       Date:  2021-07-10       Impact factor: 6.968

Review 9.  Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia.

Authors:  Mingxue Fan; Minghao Li; Lipeng Gao; Sicong Geng; Jing Wang; Yiting Wang; Zhiqiang Yan; Lei Yu
Journal:  J Hematol Oncol       Date:  2017-08-29       Impact factor: 17.388

Review 10.  Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions.

Authors:  Christian M Schürch
Journal:  Front Oncol       Date:  2018-05-18       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.